首页> 外国专利> TERT AND BRAF MUTATIONS IN HUMAN CANCER

TERT AND BRAF MUTATIONS IN HUMAN CANCER

机译:人类癌症中的TERT和BRAF突变

摘要

The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions related to certain mutations in cancer.In one embodiment, a method for treating a subject having aggressive thyroid cancer comprises the steps of (a) obtaining a biological sample from the subject; (b) performing an assay on the sample obtained from the subject to identify a mutation at 1 295 228 CT (C228T), corresponding to -124 CT from the translation start site in the promoter of the telomerase reverse transcriptase (TERT) gene, and a T1799A mutation in the BRAF gene that results in a V600E amino acid change; (c) identifying the subject as having or likely to develop aggressive thyroid cancer if the C228T and V600E mutations are identified; and (d) treating the subject with one or more treatment modalities appropriate for a subject having or likely to develop aggressive thyroid cancer. Similar approaches are applied to other human cancers harboring both BRAF V600E mutation and TERT promoter mutations.
机译:本发明涉及癌症领域。更具体地,本发明提供了与癌症中某些突变有关的方法和组合物。在一个实施方案中,一种用于治疗患有侵袭性甲状腺癌的受试者的方法包括以下步骤:(a)从该受试者获得生物学样品; (b)对获自受试者的样品进行测定以鉴定在1 295 228 C> T(C228T)处的突变,该突变对应于端粒酶逆转录酶(TERT)启动子中翻译起始位点的-124 C> T )基因,以及BRAF基因中的T1799A突变导致V600E氨基酸变化; (c)如果鉴定出C228T和V600E突变,则鉴定该受试者患有或可能发展为侵袭性甲状腺癌; (d)以适合于患有或可能发展为侵袭性甲状腺癌的受试者的一种或多种治疗方式治疗该受试者。类似的方法也适用于同时携带BRAF V600E突变和TERT启动子突变的其他人类癌症。

著录项

  • 公开/公告号WO2015153808A1

    专利类型

  • 公开/公告日2015-10-08

    原文格式PDF

  • 申请/专利权人 THE JOHNS HOPKINS UNIVERSITY;

    申请/专利号WO2015US23948

  • 发明设计人 XING MICHAEL;LIU RENGYUN;

    申请日2015-04-01

  • 分类号C12Q1/68;A61K31;A61K38;A61K39;A61P35;

  • 国家 WO

  • 入库时间 2022-08-21 15:03:43

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号